Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai acquires neuropathy product for China

This article was originally published in Scrip

Executive Summary

Eisaihas acquired sales and repackaging rights in China to alpha-Lipon 300 Stada (alpha-lipoic acid), a product for diabetic neuropathy symptoms developed by the German generics firmStada. Eisai's Chinese subsidiary will take over promotional activities from Health Vision Enterprise, a Hong Kong-based Stada development and sales subsidiary, on August 1st, and will seek approval to repackage the product at its plant in Suzhou. The anti-oxidant was launched in China in 2005 for paraesthesia (peripheral numbness) associated with diabetes. Eisai is developing the insulin secretagogue Glufast (mitiglinide, licensed from Kissei) in China, where it already markets Methycobal (mecobalamin) for peripheral nerve disorders.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts